



ADAR1 is a novel multi targeted anti-HIV-1 cellular protein

Nabanita Biswas^a, Tianyi Wang^a, Ming Ding^a, Ashwin Tumne^a, Yue Chen^a,
Qingde Wang^b, Phalguni Gupta^{a,*}

^a Department of Infectious Diseases and Microbiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA

^b Department of Medicine, Division of Hematopoiesis and Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA

ARTICLE INFO

Article history:

Received 12 July 2011

Returned to author for revision

29 August 2011

Accepted 16 October 2011

Available online 21 November 2011

Keywords:

ADAR1

HIV-1

Antiviral

Cellular protein

ABSTRACT

We examined the antiviral activity of ADAR1 against HIV-1. Our results indicated that ADAR1 in a transfection system inhibited production of viral proteins and infectious HIV-1 in various cell lines including 293T, HeLa, Jurkat T and primary CD4+ T cells, and was active against a number of X4 and R5 HIV-1 of different clades. Further analysis showed that ADAR1 inhibited viral protein synthesis without any effect on viral RNA synthesis. Mutational analysis showed that ADAR1 introduced most of the A-to-G mutations in the *rev* RNA, in the region of RNA encoding for Rev Response Element (RRE) binding domain and in *env* RNA. These mutations inhibited the binding of *rev* to the RRE and inhibited transport of primary transcripts like *gag*, *pol* and *env* from nucleus to cytoplasm resulting in inhibition of viral protein synthesis without any effect on viral RNA synthesis. Furthermore, ADAR1 induced mutations in the *env* gene inhibited viral infectivity.

© 2011 Elsevier Inc. All rights reserved.

Introduction

ADAR1 (Adenosine Deaminase Acting on RNA 1), an RNA editing enzyme, catalyzes hydrolytic deamination of adenosine to inosine (A-to-I) in completely or partially double-stranded RNA (Hough and Bass, 1994; Kim et al., 1994; O'Connell and Keller, 1994; Patterson and Samuel, 1995). This has a number of effects. The A-to-I substitution affects pre-mRNA splicing by changing the splicing site and decreases the binding of RNA to protein resulting in functional changes of the protein (Bass, 2002; Samuel, 2003). Furthermore, during mRNA translation, Inosine is recognized as Guanosine and therefore it incorporates incorrect amino acid sequence (Bass, 2002; Samuel, 2003). Because of these pluripotent properties of ADAR1, it disrupts replication of a number of RNA viruses. ADAR1 inhibits replication of hepatitis delta virus by editing of adenosine to inosine in pre-mRNA of hepatitis delta virus which eventually affects splicing of untranslated regions (Patterson and Samuel, 1995; Polson et al., 1996; Sato et al., 2001). ADAR1 was also known to edit double-stranded RNA found in the measles virus, which inhibited virus assembly and release from cells, leading to a persistent infection and development of fatal neuropathic measles infection (Horikami and Moyer, 1995). Taylor et al. (2005) showed that ADAR1-induced viral RNA editing inhibited Hepatitis C viral replication (Taylor et al., 2005). Recently Suspene et al. have shown ADAR1 induced mutation in seasonal influenza and attenuated measles viruses.

Since HIV-1 genome has several putative double stranded secondary RNA structures throughout its genome, HIV-1 RNA was considered a potential target for ADAR1. Therefore, in this report we investigated the antiviral effect of ADAR1 on HIV-1. We provided evidence that ADAR1 inhibited HIV-1 protein synthesis and viral infectivity in a variety of cells and against HIV-1 of different tropisms and different clades. We further demonstrated that such antiviral activity was at the post transcriptional stage of HIV-1 replication and that ADAR1-induced mutation at the *rev* and *env* RNA may be responsible for such posttranscriptional inhibition of viral protein synthesis. In elucidating the mechanism of ADAR1 induced inhibition of HIV-1 protein synthesis we found that ADAR1 induced A-to-G mutations in *rev* inhibited its transport activity of primary transcripts *gag*, *pol* and *env* from the nucleus to cytoplasm and thereby inhibited viral protein synthesis without any effect on viral RNA synthesis. ADAR1-induced mutations in the *env* gene further attenuate viral infectivity.

Results

ADAR1 inhibits HIV-1 protein synthesis and viral infectivity


In order to evaluate the effect of ADAR1 on HIV-1 production, 293 T cells were co-transfected with 0.1 µg pNL4.3 HIV-1 DNA and different amount of ADAR1 DNA. In each transfection assay (this one and subsequent ones), cells were also co-transfected with a luciferase-expressing plasmid DNA to control transfection efficiency. The expression of ADAR1 p150 from transfected ADAR1 DNA was analyzed by Western Blot and normalized against β-actin loading control to show the relative intensity of ADAR1 p150 expression (Supplemental

* Corresponding author at: Department of Infectious Diseases and Microbiology, 426 Parran Hall, 130 DeSoto Street, Pittsburgh, PA 15261, USA. Fax: +1 412 624 4953.

E-mail address: pgupta1@pitt.edu (P. Gupta).

Fig. 1A). Following 48 h of transfection, viral protein synthesis was quantified by measuring HIV-1 p24 in culture supernatant and intracellular HIV-1 p24 production in a cell extract by ELISA. ADAR1 inhibited

extracellular (Fig. 1A) and intracellular (Fig. 1B) HIV-1 p24 production in a dose dependent manner. With 0.7 μ g of ADAR1 containing plasmid there was an 8 fold reduction of extracellular HIV-1 p24 production in



Download English Version:

<https://daneshyari.com/en/article/6141247>

Download Persian Version:

<https://daneshyari.com/article/6141247>

[Daneshyari.com](https://daneshyari.com)